



Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers

Guest Editor:

Charles A Kunos, MD PhD

National Cancer Institute,
Division of Cancer Treatment and
Diagnosis, Cancer Therapy
Evaluation Program,
Investigational Drug Branch,
Medical Officer and Coordinator,
Investigational Therapeutics &
Radiation, Rockville, MD, USA

Deadline for manuscript
submissions:

closed (25 June 2021)

Message from the Guest Editor

Dear Colleagues,

An overarching aspect for the radiopharmaceutical drug development effort is patient and provider education through use of academic white papers on key topics. The Journal *Pharmaceuticals* has offered us the opportunity to write academic white papers for a Special Issue on “Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers.” The focus of this effort is to introduce and to describe the United States National Cancer Institutes and the academic or pharmaceutical collaborator development of these agents. Topics might range from radiopharmaceutical combination with early-phase investigational agents that test tolerability and early signs of efficacy or social aspects of this type of research, such as financial toxicity.

Some of the initial topics discussed by the NCI are found at this link to serve as a topic guide:

[https://ctep.cancer.gov/investigatorResources/
radiopharmaceutical_development_initiative.htm](https://ctep.cancer.gov/investigatorResources/radiopharmaceutical_development_initiative.htm)

Please email me at charles.kunos@nih.gov to discuss your planned topic so that there is not significant overlap in contributed material.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com
[X@Pharmaceut_MDPI](https://twitter.com/Pharmaceut_MDPI)